89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, announced yesterday that it has revealed preclinical data for its investigational drug, BIO89-100, in a late-breaking poster presentation at The International Liver Congress 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.

The product is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue in clinical development for the treatment of patients with NASH.

In this preclinical study in spontaneously diabetic obese cynomolgus monkeys, the product indicated statistically significant pharmacodynamic effects on key metabolic and liver parameters associated with NASH following weekly and every two-week subcutaneous dosing. All BIO89-100 treatment groups achieved statistically significant reductions in body weight, fasting plasma glucose, LDL cholesterol, triglycerides, and haemoglobin A1c compared to the vehicle group.